NC
VYNT

Northpointe Capital’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Northpointe Capital’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-803
Closed -$1.08M – 265
2014
Q3 		$1.08M Sell
803
-995
-55% -$1.43M 0.12% 200
2014
Q2 		$3.05M Buy
+1,798
New +$3.42M 0.29% 98

Other funds holding VYNT

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.72B AUM 7.09% 1-Year Est. Return
SCM
Sterneck Capital Management Kansas City, Missouri $233M AUM 21.98% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return

Northpointe Capital's VYNT Position: Q4 2014 in Review

Northpointe Capital sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2014, closing a stake of 803 shares — an estimated $1.08M sold.

Northpointe Capital first reported a position in VYNT in Q2 2014 and held it in 2 quarters. The position peaked at $3.05M in Q2 2014. 31 funds tracked by Wall St. Rank hold VYNT as of Q4 2014.

  • Northpointe Capital reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Northpointe Capital sold 803 Vyant Bio, Inc. Common Stock shares in Q4 2014, an estimated $1.08M.
  • Northpointe Capital first reported a position in Vyant Bio, Inc. Common Stock in Q2 2014 and held it in 2 quarters.
  • Northpointe Capital's Vyant Bio, Inc. Common Stock position peaked at $3.05M in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2014.

Based on Northpointe Capital's 13F filing for Q4 2014, filed 26 Jan 2015.